Adverse events at 1‐month · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in non‐ infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review